Seasonal Allergic RhinitisPhase 2NCT07398859
Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
A Phase 2 study testing TQH2722 injection in people with Seasonal Allergic Rhinitis, run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. at 30 sites in China.
Trial summary
This study is a multicenter, open-label, Phase II, single-arm clinical trial, with a planned enrollment of 200 to 300 subjects. Its primary objective is to evaluate the safety and efficacy of TQH2722 injection in the treatment of seasonal allergic rhinitis. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Seasonal Allergic Rhinitis
- What is being tested?
- TQH2722 injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 30 sitesChina
- Study dates
- 19 Mar 2026to Mar 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18-75, with no gender restrictions.
- Diagnosed with seasonal allergic rhinitis.
- Positive allergen test result.
- The subjects have sufficient exposure to pollen during the pollen season.
- The subject's medical history indicates that the subject had poor control of Seasonal Allergic Rhinitis (SAR) symptoms during the previous pollen season or the subject was dissatisfied with the subjective symptom control.
- Screen for subjects who have a morning iTNSS score of ≥4 on the day of screening; at baseline visit, have a morning iTNSS score of ≥4, and have an average rTNSS score of ≥4 over the past 6 days.
Show all 10Show fewer
- Good compliance during screening/induction period.
- Subjects with comorbid asthma should have stable medication use before the screening period and have their asthma condition assessed as stable by the investigator or specialist.
- The subjects voluntarily joined this study, signed the informed consent form, and exhibited good compliance.
- The subjects and their partners agree to take effective contraceptive measures throughout the entire study period (from the signing of the Informed Consent Form (ICF) to 3 months after the last administration of the trial drug).
Who cannot join
- Any abnormal laboratory test value during the screening period or randomization.
- Any disease that researchers consider to be unstable and may affect the patient's safety throughout the entire study period, or affect the study results or their interpretation, or hinder the patient's ability to complete the entire study process.
- Patients with active autoimmune diseases.
- Known or suspected immunosuppressants.
- Subjects with active malignant tumors or a history of malignant tumors.
- Screen for individuals with a history of active tuberculosis within the previous 12 months.
Show all 27Show fewer
- During the screening period, there is active hepatitis, or the presence of human immunodeficiency virus antibody (Anti-HIV) positivity, or syphilis treponema antibody (Anti-TP) positivity.
- Screen for cases diagnosed with helminthic parasitic infections within the previous 6 months, who have not undergone standard treatment or have experienced ineffective standard treatment.
- Subjects who have received specific medications or undergone any nasal or sinus surgery within the specified timeframe.
- Intravenous immunoglobulin (IVIG) therapy and/or plasma exchange within 30 days before screening.
- Screen subjects who have used monoamine oxidase inhibitors within the previous 14 days.
- Initiate allergen immunotherapy within 3 months prior to screening.
- Screen for individuals who have received attenuated live vaccines within the previous 4 weeks or plan to receive attenuated live vaccines during the study period.
- Screen for systemic Chinese herbal preparations used for the treatment of AR with short- or medium-acting systemic glucocorticoids within 4 weeks, or screen for long-acting Systemic Corticosteroids (SCS) received within the previous 6 weeks.
- Suffering from chronic active or acute infection within 2 weeks before screening or during the screening and import period.
- Patients with concomitant asthma should be excluded if they meet any of the following conditions: a. forced expiratory volume in one second (FEV1) ≤ 50% of the predicted normal value; b. acute exacerbation of asthma within 90 days prior to screening; c. currently using fluticasone propionate at a daily dose of >1000 μg/day or equivalent doses of other inhaled corticosteroids; d. assessed by the investigator or specialist as having unstable asthma.
- The subject has a concomitant disease that renders them unable to complete the screening period assessment or evaluate the primary efficacy endpoint.
- Suffering from malignant and benign tumors in the nasal cavity.
- Subjects with perennial allergic rhinitis (PAR) who are allergic to pet hair.
- Unable to use nasal corticosteroid sprays or antihistamines.
- Have a history of systemic allergy to any biological agents.
- Women who are pregnant or breastfeeding.
- Individuals who abuse alcohol, use drugs, and have known drug dependency.
- History of major organ transplantation or hematopoietic stem cell/bone marrow transplantation.
- According to the researcher's judgment, there are any medical or psychiatric symptoms that may put the subjects at risk, interfere with their participation in the study, or interfere with the interpretation of the study results.
- The forced expiratory volume in one second (FEV1) of the subject is less than or equal to 50% of the predicted normal value.
- Other reasons why the researcher believes it is inappropriate to participate in this trial.
Trial locations and contacts
30 sites in 1 country. Contact the study team or a site near you to ask about taking part.
30 sites in 1 country
China30 sites, 30 recruiting
- Not yet recruiting
Hebei University Affiliated Hospital
Baoding, Hebei, 071000
Congzhe Tian, Master, 13230238686, enttcz@163.com
- Not yet recruiting
Peking University First Hospital
Beijing, Beijing Municipality, 100034
Junxiu Liu, Doctor, 13439607635, liujunxiusanyuan@sina.com
- Not yet recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, 100044
Zhimin Xing, Master, 13681596878, xingzhimin27@163.com
- Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, 100191
Yan Yan, Doctor, 15611908358, wzyyer34@163.com
- Not yet recruiting
Cangzhou Central Hospital
Cangzhou, Hebei, 061017
Weiwei Liu, Master, 13393275339, lwwczbj@163.com
- Not yet recruiting
Hospital of Chengdu University of Traditional Chinese Medicine
Chengdu, Sichuan, 610000
Yan Xie, Master, 15008228100, xieyan000.@163.com
- Not yet recruiting
Second People's Hospital of Chengdu
Chengdu, Sichuan, 610000
Jia Chen, Master, 13980805288, 904297144@qq.com
- Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400010
Yucheng Yang, Doctor, 13452018123, yychxh@163.com
- Not yet recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310014
Weiming Hu, Doctor, 13588426686, Huwm93@163.com
- Not yet recruiting
Shandong Second Provincial General Hospital
Jinan, Shandong, 250000
Li Shi, Doctor, 13791122810, shili126@sina.com
- Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, 250012
Xuezhong LI, Doctor, 18560083535, lxzebyh@163.com
- Not yet recruiting
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, 650032
Yongmei Yu, Master, 13888532131, yuyongmei@qq.com
- Not yet recruiting
Yunnan Provincial Hospital of Chinese Medicine
Kunming, Yunnan, 650032
Chunjiang Huang, Bachelor, 13888005188, huangchunjiang-1@163.com
- Not yet recruiting
Hebei PetroChina Central Hospital
Langfang, Hebei, 65000
Jianbing Li, Bachelor, 13785658534, caoyu200211@souhu.com
- Not yet recruiting
Hebei Provincial People's Hospital
Shijiazhuang, Hebei, 050051
Yongtao Qu, Doctor, 13171807631, 35288361@qq.com
- Not yet recruiting
Hebei Medical University Third Hospital
Shijiazhuang, Hebei, 50000
Feng Luan, Master, 18533112937, lfydsylcsy@163.com
- Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, 030000
Huanping Zhang, 13994299030, zhp326@163.com
- Not yet recruiting
Tianjin People's Hospital
Tianjin, Tianjin Municipality, 300121
Jixiang Liu, Bachelor, 13512056406, 13512056406@163.com
- Not yet recruiting
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang
Yuping Yang, Doctor, 18999984998, 978288587@qq.com
- Not yet recruiting
The Central Hospital of Wuhan
Wuhan, Hubei, 430014
Wei Liu, Doctor, 15327198392, cw99990@163.com
- Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of science and technology
Wuhan, Hubei, 430022
Jianjun Chen, Doctor, 13659851719, Ylly80331@163.com
- Not yet recruiting
Tongji Hospital of Tongji medical college of HUST
Wuhan, Hubei, 430030
Rongfei Zhu, Doctor, 18986292602, zrf13092@163.com
- Not yet recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430060
Zheng Liu, Doctor, 18607110505, zhengliuent@hotmail.com
- Not yet recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710004
Kang Zhu, Master, 18991341809, zhukangent@163.com
- Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061
Fang Quan, Doctor, 13572056056, quanfang2013@163.com
- Not yet recruiting
Yan'an University Xianyang Hospital
Xi'an, Shaanxi, 716000
Ligang Zhang, Master, 15891651067, ligangzhang79@126.com
- Not yet recruiting
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000
Yuemei Sun, Bachelor, 13256383919, sunym1963@sina.com
- Not yet recruiting
The First Affiliated Hospital of Hebei North University
Zhangjiakou, Hebei, 075000
Xiaoling Shang, Bachelor, 15530396553, xiaolingshang66@sina.com
- Not yet recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, 450000
Guangke Wang, Bachelor, 13598895398, 13598895398@163.com
- Not yet recruiting
Zibo Central Hospital
Zibo, Shandong, 255036
Daowen Song, Master, 18678186682, songdaoliang1971@163.com
About this study
Official title: A Multi-center, Open-label, Phase II, Single-arm Clinical Study Evaluating the Safety and Efficacy of TQH2722 Injection Combined With Background Treatment in Subjects With Seasonal Allergic Rhinitis
This study is a multicenter, open-label, Phase II, single-arm clinical trial, with a planned enrollment of 200 to 300 subjects. Its primary objective is to evaluate the safety and efficacy of TQH2722 injection in the treatment of seasonal allergic rhinitis.
- Conditions
- Seasonal Allergic Rhinitis
- Being tested
- TQH2722 injection
- Medical subject headings
- Rhinitis, Allergic, Seasonal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TQH2722 injectionDrug
TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).
| Study group | Role | What they receive |
|---|---|---|
| TQH2722 injection | Experimental | Injection combined with TQH2722, 2 weeks as a treatment cycle. Receives: Drug: TQH2722 injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of subjects with incidence of adverse event
Adverse events occurring during treatment.
Measured: Baseline up to 4 weeks
Secondary outcomes (26)
Number of subjects with incidence of serious adverse event
Serious adverse event occurring during treatment.
Measured: Baseline up to 4 weeks
Number of subjects with incidence of abnormality check indicators
Number of subjects with incidence of abnormality check indicators: Abnormal examination indicators occurred during treatment.
Measured: Baseline up to 4 weeks
Retrospective nasal symptom score after treatment for 2 weeks
The average change in the retrospective total nasal symptom score (rTNSS) per day over 2 weeks of treatment compared to baseline. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 weeks
Retrospective nasal symptom score after treatment for 4 weeks
The average change in the retrospective total nasal symptom score (rTNSS) per day over 4 weeks of treatment compared to baseline. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 4 weeks
Mean daily morning retrospective total nasal symptom score
Mean change from baseline in the morning retrospective total nasal symptom score (AM rTNSS) at 2 weeks and 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Mean daily retrospective total nasal symptom score at night
Mean change from baseline in the Post-Medication Reviewed Total Nasal Symptom Score (PMrTNSS) at night per day at 2 weeks and 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Total instantaneous nasal symptom score before medication in the morning every day
Mean change from baseline in instantaneous total nasal symptom score (iTNSS) before medication administration in the morning, for each day during the 2-week and 4-week treatment periods. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
Measured: Baseline up to 2 and 4 weeks
Daily retrospective total nasal symptom score
Mean percentage change from baseline in daily rTNSS at 2 weeks and 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Total instantaneous nasal symptom score before medication in the morning every day
Mean percentage change from baseline in iTNSS before medication administration in the morning, for each day during the 2-week and 4-week treatment periods.
Measured: Baseline up to 2 and 4 weeks
Daily retrospective scoring of individual nasal symptoms
Mean change from baseline in daily retrospective nasal single symptom scores at 2 weeks and 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Daily retrospective nasal single symptom score during daytime
Mean change from baseline in retrospective daytime (AM) nasal individual symptom scores (rhinorrhea, nasal congestion, nasal itch, and sneezing) at 2 weeks and 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Daily retrospective nasal single symptom score during night
Mean change from baseline in retrospective nasal individual symptom (rhinorrhea, nasal congestion, nasal itch, and sneezing) scores at night (PM) at 2 weeks and 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Daily retrospective total score of ocular symptoms
Mean change from baseline in the retrospective Total Ocular Symptom Score (rTOSS) at 2 weeks or 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Total score of retrospective ocular symptoms during daytime each day
Mean change from baseline in the total daytime retrospective ocular symptom score (AM rTOSS) at 2 weeks and 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Total score of retrospective ocular symptoms each night
The average change in the retrospective total ocular symptom score (PM rTOSS) at night compared to baseline after 2 weeks and 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Total score of instantaneous ocular symptoms before medication in the morning every day
Mean change from baseline in instantaneous total ocular symptom score (iTOSS) before medication administration in the morning, at 2 weeks and 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Daily retrospective total score of ocular symptoms
Mean percentage change in total retrospective ocular symptom score from baseline at 2 weeks and 4 weeks of treatment, respectively.
Measured: Baseline up to 2 and 4 weeks
Total score of instantaneous ocular symptoms before medication each morning
Mean percentage change from baseline in total ocular symptom score immediately before medication administration in the morning, for the 2-week and 4-week treatment periods.
Measured: Baseline up to 2 and 4 weeks
Daily retrospective scoring of individual ocular symptoms
Mean change in individual ocular symptom scores from baseline to 2 weeks and 4 weeks after treatment, retrospectively assessed daily.
Measured: Baseline up to 2 and 4 weeks
Daily retrospective scoring of individual ocular symptoms during the day
Mean change from baseline in retrospective ocular symptom scores during daytime (AM) on each day at 2 weeks and 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Nightly retrospective scoring of individual ocular symptoms
Mean change from baseline in retrospective ocular symptom scores at night (PM) at 2 weeks and 4 weeks of treatment
Measured: Baseline up to 2 and 4 weeks
Quality of Life Questionnaire Score for Patients with Allergic Rhinitis
The change in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores from baseline for patients with allergic rhinitis after 2 weeks and 4 weeks of treatment.
Measured: Baseline up to 2 and 4 weeks
Daily retrospective total score of nasal symptoms
The area under the curve representing the average change in the retrospective total nasal symptom score (rTNSS) from baseline, calculated for each day during the 2-week and 4-week treatment periods.
Measured: Baseline up to 2 and 4 weeks
Blood eosinophil count and percentage
Changes in eosinophil count and percentage from baseline, as well as the percentage of change, at each evaluation visit point.
Measured: Baseline up 12 weeks
Serum total immunoglobulin E concentration
The changes in serum total immunoglobulin E concentration and the percentage of change from baseline at each evaluation visit point.
Measured: Baseline up 12 weeks
Forced expiratory volume in 1 second (FEV1) before bronchodilator administration (BD) in subjects with concomitant asthma
The change in forced expiratory volume in one second (FEV1) relative to baseline before the use of bronchodilator (BD) in subjects with asthma across all visit points.
Measured: Baseline up 12 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2026
- Study start19 Mar 2026
- Primary completionNov 2026 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Seasonal Allergic RhinitisStudies of the same condition, open and under way.
- More trials run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07398859
- Sponsor's protocol ID
- TQH2722-II-06
- Status last verified
- Nov 2025
- First submitted
- 3 Feb 2026
- Last updated
- 27 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-center, Open-label, Phase II, Single-arm Clinical Study Evaluating the Safety and Efficacy of TQH2722 Injection Combined With Background Treatment in Subjects With Seasonal Allergic Rhinitis
- ClinicalTrials.gov ID
- NCT07398859
- Acronym / sponsor ID
- TQH2722-II-06
- Conditions
- Seasonal Allergic Rhinitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 19 Mar 2026 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 10 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a multicenter, open-label, Phase II, single-arm clinical trial, with a planned enrollment of 200 to 300 subjects. Its primary objective is to evaluate the safety and efficacy of TQH2722 injection in the treatment of seasonal allergic rhinitis.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TQH2722 injection | Experimental | Drug: TQH2722 injectionInjection combined with TQH2722, 2 weeks as a treatment cycle. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Aged 18-75, with no gender restrictions.
- Diagnosed with seasonal allergic rhinitis.
- Positive allergen test result.
- The subjects have sufficient exposure to pollen during the pollen season.
- The subject's medical history indicates that the subject had poor control of Seasonal Allergic Rhinitis (SAR) symptoms during the previous pollen season or the subject was dissatisfied with the subjective symptom control.
Key exclusion criteria (27 listed)
- Any abnormal laboratory test value during the screening period or randomization.
- Any disease that researchers consider to be unstable and may affect the patient's safety throughout the entire study period, or affect the study results or their interpretation, or hinder the patient's ability to complete the entire study process.
- Patients with active autoimmune diseases.
- Known or suspected immunosuppressants.
- Subjects with active malignant tumors or a history of malignant tumors.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TQH2722 injectionTQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα). | Drug | TQH2722 injection |
Primary outcome
Number of subjects with incidence of adverse event
Time frame: Baseline up to 4 weeks
Adverse events occurring during treatment.
26 secondary outcomes
Number of subjects with incidence of serious adverse event
Time frame: Baseline up to 4 weeks
Number of subjects with incidence of abnormality check indicators
Time frame: Baseline up to 4 weeks
Retrospective nasal symptom score after treatment for 2 weeks
Time frame: Baseline up to 2 weeks
Retrospective nasal symptom score after treatment for 4 weeks
Time frame: Baseline up to 4 weeks
Mean daily morning retrospective total nasal symptom score
Time frame: Baseline up to 2 and 4 weeks
Mean daily retrospective total nasal symptom score at night
Time frame: Baseline up to 2 and 4 weeks
Total instantaneous nasal symptom score before medication in the morning every day
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective total nasal symptom score
Time frame: Baseline up to 2 and 4 weeks
Total instantaneous nasal symptom score before medication in the morning every day
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective scoring of individual nasal symptoms
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective nasal single symptom score during daytime
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective nasal single symptom score during night
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective total score of ocular symptoms
Time frame: Baseline up to 2 and 4 weeks
Total score of retrospective ocular symptoms during daytime each day
Time frame: Baseline up to 2 and 4 weeks
Total score of retrospective ocular symptoms each night
Time frame: Baseline up to 2 and 4 weeks
Total score of instantaneous ocular symptoms before medication in the morning every day
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective total score of ocular symptoms
Time frame: Baseline up to 2 and 4 weeks
Total score of instantaneous ocular symptoms before medication each morning
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective scoring of individual ocular symptoms
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective scoring of individual ocular symptoms during the day
Time frame: Baseline up to 2 and 4 weeks
Nightly retrospective scoring of individual ocular symptoms
Time frame: Baseline up to 2 and 4 weeks
Quality of Life Questionnaire Score for Patients with Allergic Rhinitis
Time frame: Baseline up to 2 and 4 weeks
Daily retrospective total score of nasal symptoms
Time frame: Baseline up to 2 and 4 weeks
Blood eosinophil count and percentage
Time frame: Baseline up 12 weeks
Serum total immunoglobulin E concentration
Time frame: Baseline up 12 weeks
Forced expiratory volume in 1 second (FEV1) before bronchodilator administration (BD) in subjects with concomitant asthma
Time frame: Baseline up 12 week
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
Related trials for Seasonal Allergic Rhinitis
RecruitingPhase 1
Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy
Birch Pollen Allergy
Active, not recruitingPhase 3
A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Enrolling by invitationObservational study
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
Pollen Allergy
RecruitingObservational study
Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure
Allergic Rhinoconjunctivitis
Recruiting
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
30 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing TQH2722 injection in people with Seasonal Allergic Rhinitis, run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. at 30 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 30 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zheng Liu, Doctor (18607110505, zhengliuent@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of subjects with incidence of adverse event (time frame: Baseline up to 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.